Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma

Annals of Surgery

Volumn 265, Issue 3, 2017, Pages 481-491

  Pasquali, Sandro ^a   Yim, Guang ^b   Vohra, Ravinder S ^c   Mocellin, Simone ^a,d   Nyanhongo, Donald ^b   Marriott, Paul ^b   Geh, Ju Ian ^b   Griffiths, Ewen A ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

adjuvant; chemoradiotherapy; chemotherapy; esophageal cancer; meta analysis; neoadjuvant; radiotherapy

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; FEMALE; MALE; MORTALITY; NETWORK META-ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL ANALYSIS;

CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; NETWORK META-ANALYSIS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84978726166     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001905     Document Type: Article

References (74)

1. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014; 371: 2499-2509
2. Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013; 381: 400-412
3. Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27: 5062-5067
4. Cen P, Banki F, Cheng L, et al. Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States. Ann Surg Oncol. 2012; 19: 1685-1691
5. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007; 8: 545-553
6. Van Meerten E, Van Der Gaast A. Systemic treatment for oesophageal cancer. Eur J Cancer. 2005; 41: 664-672
7. Cohen DJ, Leichman L. Controversies in the treatment of local and locally advanced gastric and esophageal cancers. J Clin Oncol. 2015; 33: 1754-1759
8. Gwynne S, Falk S, Gollins S, et al. Oesophageal chemoradiotherapy in the UK-current practice and future directions. Clin Oncol (R Coll Radiol). 2013; 25: 368-377
9. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007; 8: 226-234
10. Ku GY, Ilson DH. Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointest Cancer Res. 2012; 5: 85-92
11. Zhang SS, Yang H, Xie X, et al. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies. Dis Esophagus. 2014; 27: 574-584
12. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12: 681-692
13. Kidane B, Coughlin S, Vogt K, et al. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2015; 5: CD001556
14. Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011; 47: 354-360
15. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009; 27: 851-856
16. Gwynne S, Wijnhoven BP, Hulshof M, et al. Role of chemoradiotherapy in oesophageal cancer-adjuvant and neoadjuvant therapy. Clin Oncol (R Coll Radiol). 2014; 26: 522-532
17. Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014; 32: 2416-2422
18. Shapiro J, Van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16: 1090-1098
19. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012; 19: 68-74
20. Klevebro F, Alexandersson von Döbeln G, Wang N, et al. A randomised clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016; 27: 660-667. doi: 10.1093/annonc/mdw010. Epub 2016 Jan 17
21. Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013; 159: 130-137
22. Salanti G. Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012; 3: 80-97
23. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700
24. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 2011
25. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration?s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928
26. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014; 9: e99682
27. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network metaanalysis in STATA. PLoS One. 2013; 8: e76654
28. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17: 2815-2834
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188
30. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ. 2003; 327: 557-560
31. Hong H, Carlin BP, Shamliyan TA, et al. Comparing Bayesian and frequentist approaches for multiple outcome mixed treatment comparisons. Med Decis Making. 2013; 33: 702-714
32. White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J. 2011; 11: 255-270
33. Donegan S, Williamson P, D?Alessandro U, et al. Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods. 2013; 4: 291-323
34. Higgins JP, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012; 3: 98-110
35. White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012; 3: 111-125
36. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011; 64: 163-171
37. Baba M, Natsugoe S, Shimada M, et al. Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Dis Esophagus. 2000; 13: 136-141
38. Cao XF, He XT, Ji L, et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus. 2009; 22: 477-481
39. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001; 91: 2165-2174
40. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg. 1997; 114: 205-209
41. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 2003; 21: 4592-4596
42. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994; 41: 391-393
43. Boonstra JJ, Kok TC, Wijnhoven BP, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011; 11: 181
44. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997; 337: 161-167
45. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005; 6: 659-668
46. A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Japanese Esophageal Oncology Group. Chest. 1993; 104: 203-207
47. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007; 25: 3719-3725
48. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 1997; 114: 210-217
49. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004; 15: 947-954
50. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994; 73: 1779-1784
51. Lv J, Cao XF, Zhu B, et al. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol. 2010; 16: 1649-1654
52. Maipang T, Vasinanukorn P, Petpichetchian C, et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol. 1994; 56: 191-197
53. Natsugoe S, Okumura H, Matsumoto M, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006; 19: 468-472
54. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992; 16: 1104-1109
55. Roth JA, Pass HI, Flanagan MM, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg. 1988; 96: 242-248
56. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg. 1992; 127: 1446-1450
57. Tachibana M, Yoshimura H, Kinugasa S, et al. Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol. 2003; 29: 580-587
58. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26: 1086-1092
59. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001; 19: 305-313
60. Walsh T. The role of multimodality therapy in improving survival: a prospective randomised trial. In: Predicting, Defining and Improving Outcomes for Oesophageal Carcinoma. Dublin: Trinity College, University of Dublin 1995
61. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335: 462-467
62. Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003; 75: 331-336
63. Zieren HU, Muller JM, Jacobi CA, et al. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 1995; 19: 444-449
64. Van Hagen P, Hulshof MC, Van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074-2084
65. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29: 1715-1721
66. Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol. 2015; 21: 7343-7348
67. Czito BG, Palta M, Willett CG. Results of the FFCD 9901 trial in early-stage esophageal carcinoma: is it really about neoadjuvant therapy? J Clin Oncol. 2014; 32: 2398-2400
68. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20
69. Mariette C, Piessen G, Briez N, et al. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011; 12: 296-305
70. Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastrooesophageal junctional cancers. Br J Surg. 2014; 101: 321-338
71. Rees J, Hurt CN, Gollins S, et al. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer. 2015; 113: 603-610
72. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013; 14: 627-637
73. Xu Y, Yu X, Chen Q, et al. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol. 2012; 10: 173
74. Hamilton E, Vohra RS, Griffiths EA. What is the best neoadjuvant regimen prior to oesophagectomy: chemotherapy or chemoradiotherapy? Int J Surg. 2014; 12: 196-199